ACTmed

ACT Genomics (also known as ACTmed) is a leading precision oncology company based in Asia that provides comprehensive genomic profiling (CGP) services to clinicians and pharmaceutical companies. The company utilizes Next-Generation Sequencing (NGS) and proprietary bioinformatics pipelines to identify actionable mutations and guide personalized cancer treatment. Their portfolio includes tests for tissue and liquid biopsies, such as ACTOnco and ACTLiquid, which support treatment selection, monitoring, and clinical trial matching. ACT Genomics operates CAP-accredited laboratories and has a significant presence in Japan through its ACTmed joint venture with Canon Medical Systems. In 2023, the company was acquired by Prenetics Global Limited to expand its footprint in the global precision medicine market.